- Home
- ATNM vs OPRX Comparison
ATNM vs OPRX Comparison
Compare ATNM & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- OPRX
- Stock Information
- Founded
- ATNM 2000
- OPRX 2006
- Country
- ATNM United States
- OPRX United States
- Employees
- ATNM N/A
- OPRX N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- OPRX Business Services
- Sector
- ATNM Health Care
- OPRX Consumer Discretionary
- Exchange
- ATNM Nasdaq
- OPRX Nasdaq
- Market Cap
- ATNM 56.7M
- OPRX 183.1M
- IPO Year
- ATNM N/A
- OPRX N/A
- Fundamental
- Price
- ATNM $1.76
- OPRX $7.51
- Analyst Decision
- ATNM Strong Buy
- OPRX Buy
- Analyst Count
- ATNM 6
- OPRX 4
- Target Price
- ATNM $13.77
- OPRX $13.50
- AVG Volume (30 Days)
- ATNM 600.1K
- OPRX 110.2K
- Earning Date
- ATNM 10-31-2024
- OPRX 11-04-2024
- Dividend Yield
- ATNM N/A
- OPRX N/A
- EPS Growth
- ATNM N/A
- OPRX N/A
- EPS
- ATNM N/A
- OPRX N/A
- Revenue
- ATNM $81,000.00
- OPRX $83,202,506.00
- Revenue This Year
- ATNM N/A
- OPRX $43.61
- Revenue Next Year
- ATNM N/A
- OPRX $12.92
- P/E Ratio
- ATNM N/A
- OPRX N/A
- Revenue Growth
- ATNM 80.00
- OPRX 35.15
- 52 Week Low
- ATNM $1.33
- OPRX $6.92
- 52 Week High
- ATNM $10.24
- OPRX $16.65
- Technical
- Relative Strength Index (RSI)
- ATNM 25.52
- OPRX 35.83
- Support Level
- ATNM $1.88
- OPRX $7.42
- Resistance Level
- ATNM $1.85
- OPRX $8.15
- Average True Range (ATR)
- ATNM 0.16
- OPRX 0.36
- MACD
- ATNM 0.17
- OPRX -0.00
- Stochastic Oscillator
- ATNM 13.32
- OPRX 28.46
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.